A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
出版年份 2016 全文链接
标题
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
作者
关键词
Azanucleoside, Azacitidine, Decitabine, MDS, AML, HMA, Methylation, Chromatin
出版物
Clinical Epigenetics
Volume 8, Issue 1, Pages -
出版商
Springer Nature
发表日期
2016-06-22
DOI
10.1186/s13148-016-0237-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents
- (2016) Jane Merlevede et al. Nature Communications
- Myelodysplastic syndromes: Contemporary review and how we treat
- (2015) Naseema Gangat et al. AMERICAN JOURNAL OF HEMATOLOGY
- Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
- (2015) Thomas Schroeder et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
- (2015) Katherine B. Chiappinelli et al. CELL
- Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia
- (2015) Kristen Meldi et al. JOURNAL OF CLINICAL INVESTIGATION
- Myelodysplastic Syndromes, Version 2.2015
- (2015) Peter L. Greenberg et al. Journal of the National Comprehensive Cancer Network
- A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
- (2015) N Daver et al. LEUKEMIA
- Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia
- (2015) C Müller-Tidow et al. LEUKEMIA
- Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
- (2015) C. R. Cogle et al. ONCOLOGIST
- Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2’-deoxycytidine in human leukemic KG1 cells
- (2015) Stéphane Vispé et al. Oncotarget
- Epigenetic treatment of solid tumours: a review of clinical trials
- (2015) Clara Nervi et al. Clinical Epigenetics
- BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
- (2015) Thomas Cluzeau et al. Oncotarget
- Alterations of immune response of non-small cell lung cancer with Azacytidine
- (2015) John Wrangle et al. Oncotarget
- Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
- (2015) Huili Li et al. Oncotarget
- Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
- (2014) Lisa Pleyer et al. ANNALS OF HEMATOLOGY
- TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
- (2014) R. Bejar et al. BLOOD
- Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia
- (2014) C. Muller-Thomas et al. HAEMATOLOGICA
- The Epigenetic Drug 5-Azacytidine Interferes with Cholesterol and Lipid Metabolism
- (2014) Steve Poirier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Clinical development of demethylating agents in hematology
- (2014) Shyamala C. Navada et al. JOURNAL OF CLINICAL INVESTIGATION
- The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions
- (2014) Manuel Luis Orta et al. NUCLEIC ACIDS RESEARCH
- Azacitidine in untreated acute myeloid leukemia: A report on 149 patients
- (2013) Sylvain Thépot et al. AMERICAN JOURNAL OF HEMATOLOGY
- Clinical and biological implications of driver mutations in myelodysplastic syndromes
- (2013) E. Papaemmanuil et al. BLOOD
- Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes
- (2013) Yun-Gyoo Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia
- (2013) Maria Teresa Voso et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
- (2013) S. D. Gore et al. HAEMATOLOGICA
- Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
- (2013) F Traina et al. LEUKEMIA
- Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
- (2013) A Valencia et al. LEUKEMIA
- Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
- (2013) T Haferlach et al. LEUKEMIA
- RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia
- (2012) J. Aimiuwu et al. BLOOD
- Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
- (2012) M. A. Sekeres et al. BLOOD
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
- (2012) C Craddock et al. LEUKEMIA
- Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Novel Anticancer Agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for Brain Tumor Chemotherapy
- (2012) Silpa Nuthalapati et al. PHARMACEUTICAL RESEARCH
- Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
- (2011) Thomas Prébet et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
- (2011) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- (2011) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
- (2011) U Platzbecker et al. LEUKEMIA
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- (2011) R Itzykson et al. LEUKEMIA
- Clinical Effect of Point Mutations in Myelodysplastic Syndromes
- (2011) Rafael Bejar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
- (2011) Taichun Qin et al. PLoS One
- Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
- (2011) R. A. Juergens et al. Cancer Discovery
- Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group
- (2010) Katharina Götze et al. ANNALS OF HEMATOLOGY
- A novel effect of DNA methyltransferase and histone deacetylase inhibitors : NFκB inhibition in malignant myeloblasts
- (2010) Claire Fabre et al. CELL CYCLE
- A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
- (2010) Paul W. Hollenbach et al. PLoS One
- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
- (2009) T. E. Fandy et al. BLOOD
- Azacytidine Inhibits RNA Methylation at DNMT2 Target Sites in Human Cancer Cell Lines
- (2009) M. Schaefer et al. CANCER RESEARCH
- 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis
- (2009) R. Gurion et al. HAEMATOLOGICA
- Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
- (2009) David P. Steensma et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation
- (2009) M. Rius et al. MOLECULAR CANCER THERAPEUTICS
- Molecular monitoring in chronic myeloid leukemia
- (2008) Elias Jabbour et al. CANCER
- Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
- (2008) Gautam Borthakur et al. LEUKEMIA & LYMPHOMA
- Azacytidine causes complex DNA methylation responses in myeloid leukemia
- (2008) C. Stresemann et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search